Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly...

14

Ninth International Congress on Drug Therapy in HIV Infection

All scientific sessions take place in the Clyde Auditorium unless otherwise noted.

SUNDAY 9 NOVEMBER

SS1 11.00–12.30 Satellite Symposium: Pfizer HAART: Escaping the ‘Red-Queen Effect’. Will newtreatments enable us to win the evolution challenge?

SS1CH Chairs: Santiago Moreno (Spain)Mark Nelson (UK)

SS1.1 “Begin at the beginning and go on until you come tothe end. Read the directions and directly you will bedirected in the right direction” The role of CCR5 antagonists in ART-strategy; whenand how to use themJürgen Rockstroh (Germany)

SS1.2 “Curioser and curioser”Nucleoside sparing regimens: why do we need them?Graeme Moyle (UK)

SS1.3 “I think I should understand that better . . .”How important is CD4 count and how to increase it?Yves Levy (France)

Panel discussion

12.30–13.30 LUNCH

SS2 13.30–15.00 Satellite Symposium: Merck Sharp & DohmeReaching new heights in HIV management

SS2CH Chair: Brian Gazzard (UK)

SS2CH 13.30–13.35 Opening remarksBrian Gazzard (UK)

SS2.1 13.35–13.55 HIV Treatment Goals: updated guidelines and newtherapeutic opportunitiesBrian Gazzard (UK)

SS2.2 13.55–14.20 The evolving role of raltegravir in HIV managementCalvin Cohen (USA)

SS2.3 14.20–14.45 New possibilities in HIV management: real-worldexperienceChristine Katlama (France)

14.45–14.55 Panel discussion

SS2CH 14.55–15.00 Closing remarksBrian Gazzard (UK)

15.00–15.30 COFFEE

SS3 15.30–17.00 Satellite Symposium: GlaxoSmithKline PLC Pieces of the puzzle – unlocking the potential ofpersonalised medicine

SS3CH Chair: Peter Reiss (The Netherlands)

SS3CH 15.30–15.40 IntroductionPeter Reiss (The Netherlands)

SS3.1 15.40–16.00 Translating evidence into practice – efficacy of NRTIsCarlo-Federico Perno (Italy)

SCIENTIFIC PROGRAMME

15

SS3.2 16.00–16.20 Personalisation – patients and choices –understanding safety and long-term treatmentsEsteban Martínez (Spain)

16.20–16.30 Questions and answers for Professor Perno andProfessor Martínez

SS3.3 16.30–16.50 A new way of thinking – sharing experiences fromcardiovascular risk in rheumatoid arthritisGeorge Kitas (UK)

16.50–16.55 Questions and answers for Professor Kitas

SS3CH 16.55–17.00 Closing remarksPeter Reiss (The Netherlands)

17.00–17.30 COFFEE

17.30–18.00 Official Opening

Ed Byrne, Executive Dean of Biomedicine, Head ofUniversity College London Medical School (UCLMS) and Vice Provost (Health) (UK) Brian Williams, President, Royal College of Physiciansand Surgeons of Glasgow (UK)

KL 18.00–19.30 Keynote Lectures

KL1 18.00–18.30 Pathogenesis of HIV infection: implications fortreatment and preventionClifford Lane (USA)

KL2 18.30–19.00 How will we use the new ART drugs?Christine Katlama (France)

KL3 19.00–19.30 The implications beyond public health if we don’tmanage the HIV epidemicAlan Whiteside (South Africa)

19.30–20.30 WELCOME RECEPTION

MONDAY 10 NOVEMBER

O11 08.30–10.25 Antiretroviral Resistance: What You Want to Know

O11CH Chairs: Jonathan Schapiro (Israel)Anders Sönnerborg (Sweden)

O111 08.30–08.50 Global impact of HIV drug resistanceDeenan Pillay (UK)

O112 08.50–09.05 Trends in transmitted HIV drug resistance amongnon-B subtypes in the UKDaniella Chilton (UK)

O113 09.05–09.20 HIV-1 clade C resistance genotypes after firstvirological failure in a large community ARTprogrammeCatherine Orrell (South Africa)

O114 09.20–09.35 NNRTI mutations are efficiently transmitted withinclusters of new HIV infectionsMark Wainberg (Canada)

SCIENTIFIC PROGRAMME (continued)

16


SCIENTIFIC PROGRAMME (continued)O115 09.35–09.55 Importance of detecting minority variants in the

clinical management of HIVDan Kuritzkes (USA)

09.55–10.25 Panel discussion and questions

10.25–10.55 COFFEE

O12 10.55–12.40 Essential Pharmacology

O12CH Chairs: David Back (UK)Janet Darbyshire (UK)

O121 10.55–11.10 Prevalence of drug interactions betweenantiretroviral and co-administered drugs at the MOIteaching and referral hospital (Ampath), Eldoret,KenyaSaye Khoo (UK)

O122 11.10–11.25 To overdose or underdose? The question of Kaletrain children in the UK/Irish Collaborative HIVPaediatric Study (CHIPS)Sarah Walker (UK)

O123 11.25–11.45 Drug interactions that really matter Saye Khoo (UK)

O124 11.45–12.00 Efavirenz and rifampicin in the South African context:is there a need to dose increase efavirenz withconcurrent rifampicin therapy?Catherine Orrell (South Africa)

O125 12.00–12.15 Impact of efavirenz and nevirapine onpharmacokinetics of lopinavir/ritonavir as tablets andcapsules in African patientsCissy Kityo (Uganda)


12.40–14.10 LUNCH AND POSTERS (including Poster Discussion Sessions)

Hall 4, Room 1 13.00–14.00 Treatment Strategies: Naïve Patients

PCH Chairs: Brian Gazzard (UK)Alain Volny-Anne (France)

P1 Clinical effect of interleukin-2 (IL-2) immuno-adjuvanttreatment in HIV+ advanced naïve patientsCamilla Tincati (Italy)

P2 Efficacy and safety of TMC278 in treatment-naïve,HIV-infected patients: week 96 data from TMC278-C204Katia Boven (USA)

P3 Impact of antiretroviral dosing and daily pill burdenon viral rebound rates in naïve patients receiving atenofovir-based regimenAndrea Antinori (Italy)

P53 Efficacy and safety of switching from lopinavir/r toatazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week resultsJosé Gatell (Spain)

17

P54 48-week outcomes following switch from AZT/3TCto FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trialEsteban Ribera (Spain)

P306 NRTI backbone pairs for treatment-naïve adults withHIV infection: a UK economic evaluationEdward Hutt (USA)

Hall 4, Room 2 13.00–14.00 Strategies for the Experienced: Immunology and Inflammation, the Lung, and Sex

PCH Chairs: Judith Currier (USA)Simone Marcotullio (Italy)

P61 Simplification of therapy (ART) with efavirenz/emtricitabine/tenofovir DF single tablet regimen vs.continued ART in suppressed, HIV-infected patientsBen Young (USA)

P167 Effect of a fixed-dose combination of emtricitabine,tenofovir and efavirenz on adherence and treatmentacceptability (ADONE study)Franco Maggiolo (Italy)

P70 Evolution of CD4+ T-cell count in HIV-1 infectedadults receiving antiretroviral therapy with sustainedlong-term virological suppressionHelen Byakwaga (Australia)

P297 Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5antagonist SCH532706 compared with combinationtherapySarah Pett (Australia)

P213 D-dimer and anti-coagulation activity markers inchildren and adolescents with HIV infectionGiuseppe Pontrelli (Italy)

P299 What about primary pulmonary hypertension in HIVinfection in the era of combination antiretroviraltherapy?Murielle Mary-Krause (France)

P71 Virological treatment outcome under HAART: doessex matter?Annette Haberl (Denmark)

14.10–14.20 The HIV Research Trust: Report on Progress

Robert Souhami, Chairperson of the HIV Research Trust (UK)

O13 14.20–16.30 Headlines from Resource-poor SettingsIAS Session

O13CH Chairs: Pedro Cahn (Argentina)Ade Fakoya (International AIDS Alliance, and UK)

O131 14.20–14.40 Where are we with National and Internationalguidelines?Elly Katabira (Uganda)

O132 14.40–15.00 Second-line in ART in the Developing WorldJames Hakim (Zimbabwe)


18


O133 15.00–15.20 HIV/TB: when is it safe to start HAART?Robin Wood (South Africa)

O134 15.20–15.40 HIV disease management and challenges in EasternEurope and Central AsiaAlexey Bobrik (Russian Federation)

O135 15.40–16.00 Seek and treat for optimal prevention of HIV/AIDS(STOP HIV/AIDS)Julio Montaner (Canada)


16.30–17.00 COFFEE

SS4 17.00–18.30 Satellite Symposium: Boehringer Ingelheim GmbHAiming for the long-term: focus on the individual

SS4CH Chair: José Gatell (Spain)

SS4CH 17.00–17.05 Welcome and introductionJosé Gatell (Spain)

SS4.1 17.05–17.25 Considering the individual – principles of treatmentchoiceLaura Waters (UK)

SS4.2 17.25–17.50 Initiating and maintaining HAART – aiming for thelong term in treatment-naïve patientsGeorg Behrens (Germany)

SS4.3 17.50–18.20 Understanding PI resistance – aiming for the longterm in treatment-experienced patientsAnna Maria Geretti (UK)


TUESDAY 11 NOVEMBER

O21 08.30–09.50 The CNS, Immune Response and TreatmentInterruption Revisited

O21CH Chairs: Margaret Johnson (UK)Stefano Vella (Italy)

O211 08.30–08.50 HIV and the brain: neuro-inflammation long-term,CNS control of HIV replication, brain disease insuppressed patients and differential penetration of drugsDavid Clifford (USA)

O212 08.50–09.05 Rate of change in CD4 counts in patients with stableHIV viraemiaAmanda Mocroft (UK)

O213 09.05–09.20 CD4–guided STI in patients responding to HAARTFranco Maggiolo (Italy)

O214 09.20–09.35 The FOTO study: 24-week results support the safetyof a 2-day break on efavirenz-based antiretroviraltherapyCalvin Cohen (USA)


09.50–10.20 COFFEE


19

O22 10.20–12.15 Children: From Birth to Longevity

O22CH Chairs: Hermione Lyall (UK)Ian Weller (UK)

O221 10.20–10.35 Antiretroviral Pregnancy Registry (APR) at 10,000prospective reportsKaren Beckerman (USA)

O222 10.35–10.50 Treatment interruption in children with chronic HIV-infection: the results of the paediatric Europeannetwork for treatment of AIDS (PENTA) 11 trialDi Gibb (UK)

O223 10.50–11.10 Optimising paediatric treatment for long-termsurvival. Adult survivors of congenital HIV infection:what problems will they have?Hermione Lyall (UK)


O224 11.25 –12.15 Special Guest LectureThe early AIDS Epidemic in the US: views fromAtlanta and Hollywood

Harold Jaffe (UK)


CoS 12.25–13.45 Community SessionLomond Auditorium Can HAART Prevent HIV Transmission?

CoSCH Chairs: Sean Hosein (Canada)Alain Volny-Anne (France)

Earlier this year the Swiss Federal AIDS Commissionpublished a paper stating that having an undetectableviral load made HIV positive people non-infectious. This position paper has incited intense controversy,being published against a background of increasingcriminalisation of HIV transmission, difficulty ofdisclosure, and the psychological burden of living with a stigmatised and chronic illness.

The internationally renowned panel members will eachmake a 10-minute presentation on their perspective thatwill serve as a foundation for the insightful and spiriteddiscussion that will follow.

CoS.1 Bernard Hirschel (Switzerland)

CoS.2 Cate Hankins (Switzerland)

CoS.3 Paul MacPherson (Canada)

CoS.4 Bruno Spire (France)


20


SCIENTIFIC PROGRAMME (continued)Hall 4, Room 1 12.30–13.30 Adverse Events

PCH Chairs: Simon Mallal (Australia)Fiona Mulcahy (Ireland)

P128 Kidney tubular abnormalities in HIV patients treatedwith tenofovir with normal glomerular function:results of a prospective study on 284 patientsPablo Labarga (Spain)

P150 Frequency of bone abnormalities and associatedfactors in a Spanish cohort of HIV-infected patientsAnna Bonjoch (Spain)

P234 Improvement of atazanavir-inducedhyperbilirubinaemia following TDM-guided atazanavirdose reductionMassimo Giola (Italy)

P288 Predictors of immune reconstitution inflammatorysyndrome associated with Kaposi sarcoma (IRIS-KS)in a rural area of MozambiqueEmilio Letang (Spain)

P289 Impact of HIV treatment on clearance of humanpapillomavirus (HPV) infection in HIV-infectedwomenDeborah Konopnicki (Belgium)

Hall 4, Room 2 12.30–13.30 Treatment Strategies: Experienced Patients

PCH Chairs: Andrzej Horban (Poland)Andrew Phillips (UK)

P20 Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profileFrancisco Blanco (Spain)

P21 POWER 1 and 2: combined final 144-week efficacyand safety results for darunavir/ritonavir (DRV/r)600/100 mg BID in treatment-experienced HIVpatientsChristine Katlama (France)

P22 Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r)in LPV-naïve, treatment-experienced patientsChristine Katlama (France)

P23 Virological response with fully active etravirine (ETR;TMC125) after 48 weeks of treatment: pooled resultsfrom the DUET-1 and DUET-2 trialsNathan Clumeck (Belgium)

O23 13.45–15.00 Hepatic Headlines

O23CH Chairs: Antonella d’Arminio Monforte (Italy)Stephen Storfer (USA)

O231 13.45–14.00 Cryptogenic liver disease, steatosis, portalhypertension, transaminitis and antiretroviralsStanislas Pol (France)

21

SCIENTIFIC PROGRAMME (continued)O232 14.00–14.15 What’s new in hepatitis C?

Vincent Soriano (Spain)

O233 14.15–14.30 Surrogate markers for liver damage: how can wemeasure the extent of fibrosis and disease withoutbiopsy?Massimo Puoti (Italy)


CS1 15.00–16.30 Assessment of the Sick HIV-positive ReturningTraveller: Case Studies Session held in collaborationwith European AIDS Clinical Society

CS1CH Chairs: Manuel Battegay (Switzerland)Peter Reiss (The Netherlands)

Panel: Nathan Clumeck (Belgium)Bob Colebunders (Belgium)John Gill (Canada)Alison Grant (UK)Roy Gulick (USA)Christoph Hatz (Switzerland)

15.20–16.10 CasesCS1.1 • Traveller going to tropical region

Aisling Loy (Ireland)CS1.2 • Immigrant arriving from sub-Saharan Africa

Michele van Vugt (The Netherlands)CS1.3 • Traveller returning with diarrhoea

Emilio Letang (Spain)CS1.4 • Traveller returning with fever

Yves van Laethem (Belgium)

CS1.5 16.10–16.30 Mini-review: Important issues considering sick HIV-positive returning traveller or immigrant from a tropical regionChristoph Hatz (Switzerland)

16.30–17.00 COFFEE

SS5 17.00–18.30 Satellite Symposium: Bristol-Myers SquibbThe burden of choice

SS5CH Chair: Jürgen Rockstroh (Germany)

SS5CH 17.00–17.10 IntroductionJürgen Rockstroh (Germany)

SS5.1 17.10–17.35 Why NNRTIs should be the standard in treatmentinitiationMark Nelson (UK)

SS5.2 17.35–18.00 Why PIs should be the standard in treatmentinitiationCalvin Cohen (USA)

18.00–18.20 Interactive discussion sessionCalvin Cohen, Mark Nelson and Jürgen Rockstroh

SS5.3 18.20–18.30 Is choice still a burden? Keep it simple! Jürgen Rockstroh (Germany)

18.30 Close

22


SCIENTIFIC PROGRAMME (continued)ES1 18.30–20.00 Evening Symposium: AbbottLomond Clinical dialogues: Face-to-face with today’s practice Auditorium challenges

ES1CH Chair: Ed Wilkins (UK)

ES1CH 18.30–18.35 WelcomeEd Wilkins (UK)

ES1.1 18.35–18.55 Flexible treatment regimens: A prelude to improvedoutcomes?François Raffi (France)

ES1.2 18.55–19.15 Case study dialogue: Addressing the complexities of long-term ARV treatment François Raffi (France)

Panel discussionModerated by Ed Wilkins (UK), joined by Bruno Spire (France), François Raffi (France) and Pere Domingo (Spain)

ES1.3 19.15–19.35 Lipoatrophy: Untangling the differences among ARVsPere Domingo (Spain)

ES1.4 19.35–19.55 Case study dialogue: Reflecting on lipoatrophy andbody fat changesEd Wilkins (UK)

Panel discussionModerated by Ed Wilkins (UK), joined by Bruno Spire (France), François Raffi (France) and Pere Domingo (Spain)

ES1CH 19.55–20.00 Summary and closeEd Wilkins (UK)

ES2 18.30–20.00 Evening Symposium: Tibotec, a division of Hall 2 Janssen-Cilag Ltd

Spanning the treatment spectrum for HIV-1-infected patients: A new era?

ES2CH Chair: Anton Pozniak (UK)

ES2CH 18.30–18.35 Welcome and introductionAnton Pozniak (UK)

ES2.1 18.35–18.50 A new era in the management of HIV-infectedpatientsBernard Hirschel (Switzerland)

ES2.2 18.50–19.10 Optimising treatment outcomes for treatment-experienced patientsGiovanni Di Perri (Italy)

ES2.3 19.10–19.30 Providing treatment-naïve HIV-1-infected patientswith optimal careHans-Jürgen Stellbrink (Germany)

ES2.4 19.30–19.45 Looking to the future: expanding opportunitiesacross the treatment spectrumChristine Katlama (France)


ES2CH 20.00 Closing remarksAnton Pozniak (UK)

23

SCIENTIFIC PROGRAMME (continued)WEDNESDAY 12 NOVEMBER

O31 08.30–10.10 ‘Non-AIDS Morbidities’: Part of Life, HIV Diseaseand/or Adverse Events of Therapy

O31CH Chairs: David Cooper (Australia)Ray Fox (UK)

O311 08.30–08.50 Pathogenesis of non-AIDS morbidities in HIV diseaseand implications for managementSteven Deeks (USA)

O312 08.50–09.10 Cardiovascular disease; HIV, ART, immunodeficiency,pro-inflammation and other factorsJens Lundgren (Denmark)

O313 09.10–09.25 Relation between adverse effects of ARV treatmentand underlying risk in number needed to treat to harm (NNTH): myocardial infarction and abacavir useJustyna Kowalska (Denmark)

O314 09.25-09.40 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:Dstudy groupKathy Petoumenos (Australia)


10.10–10.40 COFFEE

O32 10.40–12.15 Cancer, Bone and Renal Disease

O32CH Chairs: William Powderly (Ireland)Rainer Weber (Switzerland)

O321 10.40–11.00 HIV, immune deficiency and malignancyAndrew Grulich (Australia)

O322 11.00–11.20 Bone disease and HIV: together for the long termPatrick Mallon (Ireland)

O323 11.20–11.35 High HIV viral load inhibits osteoblast function andsignallingNicholas Chew (Ireland)

O324 11.35–11.55 Management of renal disease in HIV infection for theHIV physicianIan Williams (UK)



Hall 4, Room 1 12.30–13.30 HIV-related Infections, Co-infections and Cancers: Hepatitis Co-infection (HCV and HBV)

PCH Chairs: NM Samuel (India)Mauro Schechter (Brazil)

P134 Risk factors for end-stage liver disease among HIVand hepatitis C virus co-infected patients in theSpanish VACH CohortRamon Teira (Spain)

24


SCIENTIFIC PROGRAMME (continued)P135 Screening for liver fibrosis in HIV-mono-infected

patients with increased ALT comparing FibroScanwith FIB-4Stefan Mauss (Denmark)

P264 Cross-sectional study to determine prevalence ofsignificant liver fibrosis (F2-F4) in HIV/HCV co-infected patients: GRAFIHCO studyAngel Burgos (Spain)

P265 A 4-year follow-up of a cohort of HIV-positivecirrhotic patientsPaula Tuma (Spain)

P266 Rapid virological response is the best predictor forachieving SVR under peg-IFN/ribavirin hepatitis Ctherapy in HIV/HCV co-infected patientsJürgen Rockstroh (Germany)

P267 Switching from zidovudine/lamivudine (ZDV/LMV) totenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/LMV) in HIV/HCV co-infection (COTKI study)Paola Nasta (Italy)

P268 HCV relapse after peg-interferon (IFN) plus ribavirin(RBV) therapy: is 12-week follow-up enough todetermine sustained HCV clearance?Jose Medrano (Spain)

Hall 4, Room 1 12.30–13.30 Laboratory Monitoring of Disease and Therapy

PCH Chairs: Saye Khoo (UK)Veronica Miller (USA)

P178 Re-evaluation of resistance algorithms forlopinavir/ritonavir in the TITAN trialVincent Calvez (France)

P197 Validation of an enhanced sensitivity Trofile™ HIV-1co-receptor tropism assay for selecting patients fortherapy with entry inhibitors targeting CCR5Jacqueline Reeves (USA)

P198 Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected withClade C virusSybil Eng (USA)

P199 Therapeutic drug monitoring of new formulationKaletra in pregnancyLaura Else (UK)

P241 Modelling the change in lopinavir apparent oralclearance over time following cessation oflopinavir/ritonavir: data from the TAIL studyLaura Dickinson (UK)

25

SCIENTIFIC PROGRAMME (continued)O33 13.45–15.00 Important Recent Findings from Cohort Studies

O33CH Chairs: Cristina Mussini (Italy)Jeff Nadler (USA)

O331 13.45–14.00 Patterns of viral suppression on cART as predictorsof uncontrolled viraemia after starting a newantiretroviral after 1 January 2003Joanne Reekie (UK)

O332 14.00–14.15 Opportunistic infections in immunocompromised butvirologically suppressed HIV-1 infected patientsWendy Bannister (UK)

O333 14.15–14.30 Treatment discontinuation and virological failureamongst HIV-positive individuals starting second-linecombination antiretroviral therapy (cART)Colette Smith (UK)


CS2 15.00–16.30 Update on the Clinical Management of ComplexHIV/AIDS Cases: Interactive Session held incollaboration with IAS-USA

CS2CH Chairs: Roy Gulick (USA)Ian Williams (UK)

Panel: Judith Currier (USA)Cristina Mussini (Italy)

CasesCS2.1 • Strategies for antiretroviral therapy

Roy Gulick (USA)CS2.2 • Co-morbidities and complications that impact

antiretroviral decisionsIan Williams (UK)

CS2.3 • Current issues in viral hepatitis co-infection with HIVJürgen Rockstroh (Germany)

16.30–17.00 COFFEE

SS6 17.00–18.30 Satellite Symposium: Gilead Sciences Europe LtdUnderstanding and overcoming the challenges of latepresentation of HIV patients

SS6CH Chair: Jürgen Rockstroh (Germany)

SS6CH 17.00–17.10 WelcomeJürgen Rockstroh (Germany)

SS6.1 17.10–17.30 The epidemiology of late presentation in HIVCaroline Sabin (UK)

SS6.2 17.30–17.45 Strategies to encourage earlier presentation anddiagnosis: The European experienceAntonio Antela (Spain)

SS6.3 17.45–18.00 Strategies to encourage earlier presentation anddiagnosis: The US experienceYvette Calderon (USA)

SS6.4 18.00–18.20 Current and emerging treatment approaches for late-presenting patientsPatrick Mallon (Ireland)

26


SCIENTIFIC PROGRAMME (continued)SS6CH 18.20-18.30 Summary and close

Jürgen Rockstroh (Germany)

18.30–20.00 POSTER RECEPTION

THURSDAY 13 NOVEMBER

O41 08.30–10.00 Hot Topics and Late Breakers 1

O41CH Chairs: Eric Sandström (Switzerland)Schlomo Staszewski (Germany)

O411 08.30–08.50 HIV–TB co-infection and TB drug resistance: anemerging threat to HIV and TB programmesGerald Friedland (USA)

O412 08.50–09.05 Factors associated with poor clinical outcome amongHIV-infected patients with TB in Europe andArgentina. The HIV/TB collaborative studyDaria Podlekareva (Denmark)

O413 09.05–09.20 Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naïve HIV-1 infected adultsThomas Kakuda (USA)

O414 09.20–09.35 48-week data from Study AVX-201: a randomisedphase IIb study of apricitabine in treatment-experienced patients with M184V and NRTIresistanceSusan Cox (Australia)

O415 09.35–09.50 Efficacy and safety of 48-week maintenance with QDATV vs. ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: Study AI424136Santiago Moreno (Spain)


10.00–10.30 COFFEE

O42 10.30–12.05 Hot Topics and Late Breakers 2

O42CH Chairs: José Gatell (Spain)Ian Weller (UK)

O421 10.30–10.50 When to start therapy? The patient’s viewpointGus Cairns (UK)

O422 10.50–11.05 Do the disadvantages of late initiation of HAARTpersist in patients achieving and maintaining viral loadsuppression for a year on HAART?Laura Waters (UK)

O423 11.05–11.20 Risk of new AIDS-defining events in patients withadvanced immunodeficiency during suppressiveHAART: results from the German ClinSurv cohortAlexander Zoufaly (Germany)

O424 11.20–11.35 Resistance development in virological failures withDRV/r or LPV/r: 96-week analysis of the Phase IIITITAN trial in treatment-experienced patientsSandra De Meyer (Belgium)

27

SCIENTIFIC PROGRAMME (continued)O425 11.35–11.50 Efficacy and safety of maraviroc in treatment-

experienced patients infected with R5 HIV-1: 96-week combined analysis of MOTIVATE 1 and 2 studiesDavid Hardy (USA)


12.05–12.15 Closing Remarks

12.05–12.10 Closing comments from the EATG representativeWim Vandevelde (Portugal)

12.10–12.15 Closing comments from the Congress ChairpersonIan Weller (UK)

12.15–13.00 LUNCH AND CLOSE OF CONGRESS

KEYNOTE LECTURERSWe are delighted to have secured contributions from the following internationally renownedindividuals and hope that the information below will be of interest in relation to the KeynoteLecture session on Sunday evening following the Official Opening.

Christine Katlama has worked in the field of HIV since 1982 and wasinvolved in the discovery of HIV-2 in 1986. Her group first demonstratedthe impact of HAART on immune reconstitution and works extensively inthe field of new drugs and resistance.

Professor Katlama is a founder member of ORVACS, which is developinga therapeutic vaccination programme for HIV-infected patients. As afounder and President of Solthis (Solidarité Thérapeutique & InitiativesContre Le SIDA), a non-governmental organisation, she is also heavilyinvolved in access to HIV treatment and education in developingcountries.

Professor Katlama was President of the European AIDS Clinical Society until July 2004, and remainsan active member, involved in many educational initiatives. She is a member of the editorial boardsof several journals, including HIV Medicine and AIDS.

Christine Katlama, Professor of Infectious Diseases and Head of the AIDSClinical Research Unit, Pitié-Salpêtrière Hospital, Paris, France

76


AUTHOR INDEX

Aarons, L P241 Abad, F P162 Abdalla Elteer, A P214 Abdel-Kader, L P141 Abdon, A P78 Abrescia, N P3 Absalon, J P8, P136* Abu Bakar, M P305* Acinapura, R P166 Ackad, N P81 Adesola, O P172 Adeyemi, A P172* Adorni, F P34 Adorni, FA P194 Aggett, S P229* Agostinone, A P152 Agud Aparicio, J P93, P100,

P173 Aguirrebengoa, K P33 Ahmed, N P227 Ahmed, S P79 Aich, B P193 Airoldi, M O213, P167 Álamo del Rodríguez, M P93 Alas, B P68 Albalate, M P128 Alcalde-Encinas, M P164, P254 Alcarez, C P33 Alcorn, K O421 Alessandra M. Martino, A P214Ali S. Bengleil, A P214 Allavena, C P26* Allegri, G P313 Almasi, F P46*, P287* Almeida, I P51 Almeida, J P288 Aloisi, M P177 Alonso, P P288 Altclas, J O414Alterio, L P152 Altice, F P240 Álvarez, Á P89 Álvarez, M P54, P78 Ambar, R P196, P209 A-Megido, J P290 Amiramini, S P212 Ammari IME P214Ammassari, A P3, P166 Amoroso, A P121An der Heiden, M O423 Ancock, B P116* Andersen, T P90 Anderson, J O422, P73*, P203 Andrade, M P89Andreoni, M P3, P56 Andrews, L P240 Angeletti, G P118Anghel, N P257 Antela, A SS6.2, P44

Antinori, A P3*, P166, P169,P179, P292

Antinori, S P274 Antoniadou, A P186, P294 Antonopoulou, S P105 Apostolova, N P120, P161* Aquilina, C P29 Arama, V P255 Arastéh, K P24 Arazo, P P64 Arbune, M P261* Arechavala, A P252 Arildsen, H P90 Arranz, J P53 Arredondo, M P20 Arribas, J P44, P64, P308 Arumainayagam, J P15 Asghar, A P248* Ashby, J P260 Aster, V P295* Avidor, B P188 Avihingsanon, A P244* Awni, W P95, P101, P245,

P247 Awunor, C P149 Ayala, E P288 Ayoub, A P154* Azijn, H P181, P189

Babu, C P79 Back, D O121, O12CH, P6,

P233, P237, P238, P250 Badal-Faesen, S P198 Bai, F P1, P88, P97, P167 Baietto, L P233 Bailey, A P260, P262* Bailey, M P297 Baily, G P203 Bakoyiannis, G P124 Balcarek, K P147 Baldelli, F P10, P84, P118 Balestra, P P292 Balle, N P174 Ballesteros, D P120, P161 Ballestri, S P139, P140 Balogh, A O415 Bambumba, A P79 Bandivdekar, A P211 Bánhegyi, D P22 Bannister, W O332* Barassi, A P235 Barda, B P202 Barker, R P262 Barlow, P P289 Barranger, E P222 Barreiro, P P128, P137, P138,

P265, P268, P284, P286 Barrieshee, A P278* Barrios, A P173, P251

Barros, C P173 Barrufet, P P92 Basilico, C P234 Bassaris, H P124 Bastos, R P288 Battegay, M CS1CHBatuca, J P96 Baumgardt, C P32 Baumgarten, A P7, P75 Baxter, J P190, P192* Beauvoit, B P147, P148 Becker, E P304* Beckerman, K O221* Bedimo, R P9* Beets, G P23, P27 Beghetto, B P115, P156, P300 Behrens, G SS4.2Beijnen, J P242 Belaebi, L P46 Belda, A P162 Bele, V P193 Belfiori, B P84 Bellagamba, R P292 Bellido, R P142 Bellistrì, G P1, P88, P97 Bellos, N P21Benea, O P255, P261Benetucci, J P252 Bengleil, AS P214Beniowski, M O331Berenguer, J P54 Berg, J P315 Berg, T P201 Berger, F P135, P160 Bergin, C P132, P155, P276,

P293 Bergman, J P222 Bernardi, S P213 Bernasconi De Luca, D P234 Bernstein, B P95, P101, P110,

P245, P247 Berry, A P249 Bertheau, P P269 Bhatti, L P190, P192 Biagetti, C P123 Bickel, M P18*, P32, P59*,

P122 Bigoloni, A P45 Bijuklic, K P200 Billing, N P98* Bini, T O213, P88, P153, P167,

P235 Bino, S P87 Biondi, M P235 Bisi, L P167, P273 Bisicchia, F P17 Bisimba, J P175*Bissé, E P210 Bissio, E P317*

Name Activity Name Activity Name Activity

*Indicates presenting author.

77

AUTHOR INDEX (continued)

Blanc, C P38 Blanco, F P20*, P42, P66,

P128, P137* Blanco, JL P64Blanco JR P64 Blas-García, A P120*, P161 Blaxhult, A P82 Bobrik, A O134* Bodtlaender, A P59 Boffito, M P241 Bogner, J O212 Bolan, R P303Bonfanti, P P19, P74 Bonjoch, A P50*, P150* Bonnet, J P147, P148 Bonora, S P233 Boorman, H P28 Boothby, M P113* Borderi, M P123* Borghi, V P273* Borras-Blasco, J P162* Boschi, A P30 Bossola, M P177 Bottecchia, M P284 Bottieau, E P270, P283* Bouzas, M P252 Bovee, I P208 Boven, K P2*, P239 Bower, M P14, P49, P116,

P248 Boyce, C P121 Boyd, K O122 Boyd, M P70 Boyle, N P199 Bracciale, L P168 Bradbeer, C P305 Branco, T P96, P155 Brandolini, M P56 Braun, P P12, P43, P201Bravenboer, B P55 Bravo, I P65 Bray, D P206 Breiden, J P246 Brennan, M P199, P246 Brenner, B O114 Brodt, H P32 Brogan, A P306, P309 Brosa, M P314 Bruce, R P240*Brun, F P92 Bruyand, M O314, O412 Buelens, A P239 Burapat, C P259 Burger, D P244 Burgos, A P80, P117, P264*,

P308 Burk, M P188 Butler, K O122 Buvé, A P223

Buxton, G P107* Buzon, M P50 Byakwaga, H P70*

Caballero, E P40 Cabie, A P26 Cabrero, E P80, P117, P264,

P308 Caffagni, G P140 Cahn, P O414 , O13CHCain, K P259 Cairns, G O421* Cairns, V P41 Caixas, U P96 Calbi, M P99 Calcagno, A P233 Caldas, C P296* Calderon, Y SS6.3Callegaro, A O213 Caluwaerts, S P223 Calvez, V P29, P178* Calza, L P165 Camacho, R P51 Camanni, G P10, P118* Cambrea, S P226* Campbell, L P260* Candido, V P196 Canestri, A P38* Cañizal, A P252 Cano-Sánchez, A P164, P254 Capasso, M P39 Capetti, A P31* Caramma, I P274 Carcaba, V P290 Cardellach, F P142, P143,

P144, P146 Cardoso, S P296 Carganico, A P13, P25 Carini, E P45 Carlebach, A P18 Carocci, C P69* Carosi, G O415, P52, P267,

P282 Carradori, S P74 Carrilho, C P288 Casado, J P80* Casana, M P88, P97, P153*,

P235* Casas, E P65, P173 Caseiro, M P196, P209 Casillas Rodriguez, J P104,

P108 Cassetti, I O414, P4 Castagna, A P36, P37, P45,

P202 Castaño, M P141 Castera, M P162 Castilla, V P251 Castro, A P42, P92

Castro Lopez, H P104*, P108* Cattelan, A P56 Cauda, R P99, P243 Caum, C P150 Caumes, E P269 Cavassini, M P231 Caylá, J O412 Ceccherini-Silberstein, C P35,

P179 Cecchini, D P252* Celesia, B P17* Cervero, M P173* Cervero Jiménez, M P93*,

P100* Cesari, M P1, P274 Chadwick, D P107 Chaikan, A P237* Chandramani, S P15 Chanmano, S P244 Charles, M P229 Charlotte, F P269 Chaudhary, M P310 Chauret, N P298 Chein, M P303 Cheng, A P4 Chernai, N P222 Chew, N O323*, P109* Chiavaroli, R P106, P131 Chierakul, N P237 Chiesa, E P206 Chiesi, A O331Chilton, D O112* Chini, M P47, P105 Chiodo, F P123 Chiotan, C P255 Chirianni, A P3 Chiu, Y P95 Chranioti, K P294 Christensen, J P90 Christie, A P315 Chuah, J P72 Chuchuttaworn, C P237 Chui, Y P245, P247 Cicconi, P P153, P235 Cingolani, A P168 Ciraru-Vigneron, N P222* Citton, R P213Clark, D P203* Clay, E P303 Clerici, M P206 Clermont, P P298 Clifford, D O211* Clotet, B O331, P23, P33, P42,

P50, P54, P58, P64, P65, P67,P114, P142, P150, P157, P171,

P176, P191, P272* Clumeck, N P23*, P48, P289 Coakley, E P190, P197 Cobos-Trigueros, N P164, P254



78



Coelho, R P296 Coen, M P206 Cohen, C O214*, SS2.2, SS5.2,

P157 Cohen, D P110, P170 Cohen, K O124 Colafigli, M P243 Colberg, K P62 Colby, D P77 Colebunders, R P228, P270 Cologni, G P52, P282 Colson, A O214 Comi, L P88, P97, P153, P235 Compagnucci, A O222 Compangocci, A P46 Comparini, R P209 Conner, C P121, P240 Contés, E P251 Conway, B P81*, P277*, P278 Cooper, C P28 Cooper, D O414, O31CH, P70,

P244, P297 Cordes, C P2 Córdoba, M P20 Coria Ramirez, E P108 Corpolongo, A P3 Corsi, C P69 Corso, N P133 Cortés, C P92 Cosín, J P53, P78, P134 Cossarini, F P202 Costagliola, D P299 Costarelli, S P52 Cotter, E O323 Coulter-Smith, S P199, P246 Couto-Parada, X P203 Covington, D O221 Cox, S O414* Cozzi-Lepri, A P183 Crauwels, H P239* Crespo, M P40 Cristina, M P88 Cui, Y P247 Cuko, G P153 Cupsa, A P257 Curran, A P40, P54 Currier, J PCHCurtin, J P57 Cusato, M P234 Cuthbertson, Z P6, P250 Cuzin, L P26

Da Cunha, C P22 Da Silva, B P95, P101*, P110*,

P245 Daikos, G P186 D’Alessandro, M P19D’Amico, R P125, P139, P140

Daniels, R P14* d’Aquin Toni, T O114 Darbyshire, J O12CH d’Arminio Monforte, A O314,

O332, O23CH, P1, P88, P97,P153, P235

D’Arrigo, R P35, P179 Das, A P28 Das, S P15*, P113 Däumer, M P201 Davies, A P91 Davies, G P237 Davis, C P121* D’Avolio, A P233 de Barra, E P132, P293 de Béthune, M O424, P189 De Boer, M P283 de Gaetano Donati, K P99* De Gennaro, M P206 de Guzmán, M P251 de la Calle, O P314 De la Torre, J P65, P112 de Lazzari, E P53 De Longis, P P169 De Luca, A P99, P168, P243 De Meyer, S O424*, P21, P24,

P181, P189 De Pablo-Bernal, C P89 De Paepe, E O424 De Silvestri, A P30 De Smedt, G P23, P27, P189,

P272 De Socio, G P19, P74 De Terlizzi, F P215 De Wit, S O314, P36, P37,

P48*, P289 De Wolf, H P205 Deeks, S O311* Degen, O P62*Deig, E P78, P146 DeJesus, E O214, O413, P61,

P63 del Álamo Rodríguez, M P100 del Arco, A P102 Delforge, M P48, P289 Delfraissy, J O415 Delgado, C P51Delgado-Alves, J P96 Della Torre, L P202 Dellamonica, P P26 Deloof, A P205* Delpech, V O112 Demeester, R P283 Demopoulos, C P105 Deshpande, A P211Deveaud, C P147, P148 DeWet, J P81Di Biagio, A P215 Di Castelnuovo, A P99

Di Giambenedetto, S P168,P243

Di Masi, F P152 Di Matteo, L P152 Di Perri, G ES2.2, P233 Di Vincenzo, P P39, P194 Diaz, M P40 Diaz, R P209 Dickinson, L P237, P241* Diderichsen, P P245 Dierynck, I O424, P189 Dietz, B P307, P311, P312 Diniz, A P51 Doan, T P95, P101 Dobosz, S P216*, P217 Doerholt, K O122 Dolara, A O213 Domingo, P ES1.3, P42, P53,

P67, P134, P191 Dominguez, K O221 Doran, P O323 Dragsted, U P6, P250 Dravid, A P193 Drechsler, H P9 Duarte, N P196 Dufty, N P249 Duiculescu, D P224, P275* Dumitrescu, F P257* Duncan, A P204 Duncan, F P277 Dunlop, W P310* Duvivier, C P26

Eberhard, A P195 Eberle, J P200 Eberle, S P86 Ebrahimi, R P61, P63 Eccleston, K P79* Echeverría, P P53, P65*, P67*,

P150 Edwards, C P91Edwards, I O121 Egle, A P200 Egnell, K P256 Ehret, R P43 ELA Group*, P65 Elbasha, E P310Elion, R O214 Ellis, E P219, P225 El-Sadr, W O314 Else, L P6, P199, P241, P246,

P250*Elteer A P214 Emery, S P70, P297 Emmelkamp, J P266, P304 Ene, L P275 Enejosa, J P4 Eng, S P198* England, K P218*



79


English, S P103* Epting, T P210 Eron, J P27 Esplugues, J P89*, P120, P161 Esposito, R P34, P125, P273,

P300 Esser, S P41*, P76* Estany, C P150 Estrada, V P54 Etzel, A P4 Everhard, F P306, P309 Evers, S P163

Fabbiani, M P243*Fakoya, A PCH Falco, V P40 Fang, W P240 Fantoni, M P99 Farajallah, A P8, P61, P63 Fardel, V P231 Farrell, G P276 Fätkenheuer, G O425, P12,

P157*, P195, P266 Fernandez, S P112 Ferramosca, S P39 Ferreira, A P296 Ferreira, D P296 Ferrer, E P44, P53, P92 Ferrer, M P114, P171, P176 Ferrer, P P54, P78FHDH-ANRS 04, the P299 Filice, C P119 Firlag-Burkacka, E P184 Fisher, M O332, O422Fituri, OA P214 Flaherty, J P61, P63 Flamm, J P157 Flandre, P P26 Fleming, C P199 Florence, E P36*, P37, P228*,

P270*, P283 Flores, J P64 Floyd, S P11 Foggia, M P3 Fomundam, H P73 Fontas, E O314 Forbici, F P179 Force, L P92 Fortuny, C P143, P144 Fox, R O31CH, P103, P219,

P225, P253*, P291 Fox, S P68 Fox, Z P183 Francisci, D P10, P84*, P118 Francque, S P270, P283 Fraser, C P277 Fredrick, L P110Freedberg, K O113 Friedland, G O411*, P240

Friend-du Preez, N P73Friis-Møller, N O313, O314 Fumaz, C P114, P171*, P176* Furrer, H O412 Fusetti, G P45

Gagliani, L P196, P209 Gaikwad, S P193 Galani, L P294 Galindo, M P134 Gallagher, L P277 Gallego, M P102 Galli, L P45, P202 Galli, M P1, P39, P119, P194,

P274 Gallo, C P290 Gallo, L P12, P76 Garb, J O214 Garcia, M P33, P58 García, P P146 García Benaya, E P93, P100 García Lacalle, C P93, P100 Garcia-Alcalde, M P134 García-Bujalance, L P314 García-García, J P164, P254 García-Henarejos, J P42, P44,

P164, P254 García-Samaniego, J P268,

P284 Gargalianos, P P124, P186 Garrabou, G P142*, P143,

P144, P146* Garraffo, R P26 Garren, K P312 Garrido, C P20 Garrido, M P134 Garvey, L P301* Gascon, J P288 Gaspar, G P173, P251* Gatell, J O332, O42CH, SS4CH,

P53*Gathercole, L P113 Gatti, F P52*, P267, P282 Gazzard, B SS2CH, SS2.1, PCH,

P14, P16, P49, P116, P129,P151, P248

Geijo, P P42, P92, P134 Genoway, K P277 Georgoulakis, J P294 Geretti, AM SS4.3Germano, I P96 Gersbacher, E P195 Gervasoni, C P119 G-Franco, A P290 Ghaji, N P149 Ghanem, M P15 Giamarellou, H P124, P294 Giancola, M P166, P169 Gianelli, E P74

Giannaris, M P124 Gianotti, N P3, P45 Giaquinto, C O222 Gibb, D O122, O125, O222* Gibbons, S O121, P199, P233,

P246 Gibbs, S P110 Gibellini, D P123 Giffo, B P29 Gilks, C O125 Gilliam, B P121 Ginocchio, F P215 Giola, M P234* Girardi, E O412 Gisolf, E P55, P60 Giubelan, L P257 Giulianelli, M P169 Giuntini, R P74 Gizinska, J P258 Goelz, J P195 Gogos, H P124 Goikoetxea, J P33 Goldbach, J P41 Golegã, A P209 Gölz, J P76 Gómez-Sirvent, J P221Gómez-Sucerquia, L P161 Gonzalez, A P130, P302 González, M P221 González, Y P161Gonzalez-García, J P264 González-Lahoz, J P20, P128,

P137 Gonzalez-Mena, A P64 González-Mestre, V P114 González-Pardo, G P66 Goodrich, J O425, P154 Gorèíková, J P212 Gori, A P97, P167 Gori, C P35 Gorowara, M P244 Graf, B P16* Grana, M P102, P112 Grancea, C P182 Granholm, H P82 Granier, C P83 Grant, D P110Grebely, J P277 Green, H O112, O222 Gregis, G O213 Greil, R P200 Griffa, L P80, P117*, P264 Grima, P P106, P131 Grima, PF P106*, P131* Grimm, K P63 Grinsztejn, B P21, P24 Grisaru, G P188 Groeneveld, P P55 Grossi, P P234



80



Grosskurth, H P11 Grosso, C P74 Grulich, A O321* Guaraldi, G P34*, P94*, P115,

P125*, P139*, P140*, P156,P177, P300*

Guatelli, K P196 Guelar, A P130, P302* Guevara, F P20 Guiget, M P269 Gulick, R O425, CS2.1, CS2CHGulizia, R P119* Gupta, A P16 Gupta, N P158 Gupte, N P193 Gussio, M P17 Gute, P P18, P32 Gutierrez, F P53 Gutierrez, M P67 Gyllensten, K P82*

Haas, B P83 Habel, A O214 Haberl, A P32, P71*, P76 Haigney, Z O413 Hain, J P86*Haine, D P81Hairrell, J P110 Hakim, J O132* Hamlyn, E P260 Hamouda, O O423 Han, D P197 Hanhoff, N P71 Hankins, C CoS.1Hanna, G P185 Hanzlíková, J P212 Hardy, WD O425* Harris, M P271 Harrison, L O112Hartkoorn, R P238 Hartmans, N P208 Harxhi, A P87* Hassoun, G P188 Hatz, C CS1.5Hatzakis, A P47, P186 Haubrich, R P27*, P312 Hay, P P6, P250 Heera, J O425 Hegener, P P135, P160 Hemmett, L P313 Henke, J P135, P160 Hennessy, M P91, P236 Hepburn, M P219, P225 Hernandez-Quero, J P42, P64 Herrero-Segastume, V P164,

P254 Hertling, S P62 Hervás, R P173 Hervey, C P207

Hill, A P5*, P36, P37, P127,P178, P181

Hirschel, B CoS.2, ES2.1HIV/TB Study Group O412 Hjelmgren, J P313 Hodder, S P63* Hoepelman, A P60 Hoepelman, I P55 Hoetelmans, R P239 Höhn, C P43 Høj, L O313, P183 Hojman, M P227* Holas, C P95 Holm, S P71 Holmes, P P14, P248 Holodniy, M P9 Horban, A PCH, P184 Hornberger, J P318 Hosein, S CoSCHHosseina, M P277 Hristea, A P255 Huang, W P197 Hughes, P P11 Huitema, A P242 Hull, M P271* Husstedt, I P163* Hutt, E P306*, P309*

Iacoviello, L P99 Iannotti, N P99 Ibrahim, F P262 Idris El Ammari, I P214 Ilie, M P226 Imaz, A P40* Ionescu, C P275 Iosipenco, M P255 Iribarren, J P33, P221, P314 Isaacs, R P207 Isenman, H P248 Ive, P O124, P2 Iwuala, S P126* Izopet, J P26

Jackson, A P276 Jackson, AGA P129, P151 Jackson, F P83 Jackson, V P199*, P246 Jadhav, S P211* Jaegel-Guedes, E P195 Jaeger, H P7, P13, P25, P41,

P75, P195 Jaffe, H O224* Jan, E P91 Janke, M P266 Jansen, K P272 Jarrin, I P279 Jauer, M P200 Jayasuriya, A P249

Jensen, J O214 Jimenez, I P268 Jiménez-Nácher, I P66 Johnson, M O333, O21CH, P6,

P23, P83, P250 Judd, A O122 Jullien, V P287 Jusdado, J P251 Jusdado Ruiz-Capillas, J P93,

P100

Kabeya, K P48 Kachman, E P188 Kaiser, R P201 Kakuda, T O413*, P272 Kalath, T P257Kambraki, M P214 Kanjavanit, S O222 Karafoulidou, A P47, P186 Karaiskos, I P294 Karakitsos, P P294 Kasteren, M P55 Katabira, E O131* Katlama, C KL2*, SS2.3, ES2.4,

P21*, P22*, P26, P38, P269,P272

Katsarolis, I P294 Kavatha, D P294 Kawiya, J O125 Kedem, E P188 Kelleher, A P297 Kelly, S P132* Kerndt, P P303 Kerr, S P244 Kestens, D P239 Khanna, M P158 Khatib, N P49 Khaykin, P P32, P122 Khoo, S O121*, O123*, O125,

PCH, P6, P199, P233, P237,P238, P241, P246, P250

Kiely, B P293 Kieran, J P246, P276* Kigen, G O121Kim, D P247 Kimaiyo, S O121 Kinder, F O214Kint, I P223*, P228 Kirk, O O212, O313, O332,

O412 Kirschner, J P147, P148 Kiss, L P197 Kitas, G SS3.3Kittikraisak, W P259 Kityo, C O125*Kjær, J P183* Klauke, S P12, P18, P32, P59 Klein, C P95*, P101, P245,

P247



81


Knecht, G P13, P25, P59, P122 Knechten, H P12, P13*, P25,

P43*, P195 Knight, E P277 Knobel, H P53, P130, P302 Koegl, C P75* Koeppe, S P25 Kok, P P263 Kollan, C O423 Komninakis, S P196, P209 Konig, J P295 Konopnicki, D P289* Kontos, A P85 Koole, O P228 Koopmans, P P55 Körber, A P76 Kordossis, T P85*, P186 Kourkoudi, S P124 Kovacs, C P81 Kowalska, J O313* Kraemer, S P29 Kraja, D P87 Kreuzberg, C O423 Krivine, A P46 Ktorza, N P38 Kumar, R P72, P310 Kumarasamy, N P72, P111 Kumari, B P15 Kuritzkes, D O115* Kurowski, M P59 Kwan, W P238

La Rosa, R P17 Labarga, P P128*, P137, P265,

P268 Lacombe, K O212 Lafuente-Lafuente, C P279 Laird, J P291Lalezari, J O413 Lallemant, M O222 Lambert, J P109, P199, P246* Lampe, F O333 Lampreia, F P96 Lane, HC KL2* Larrouse, M P54 Larson, J P197 Lascoux-Combe, C P299 Lataillade, M P180*, P185 Latarska-Smuga, D P258 Laterreur, J P298 Lathouwers, E O424 Lattanzi, A P94 Lattimore, S O112 Lauriola, M P206 Laursen, T P174 Law, M O314Lazanas, MC P47, P105, P186 Lazanas, ML P124

Lázaro, P P308 Lazzarin, A O415, P21, P45,

P76, P202, P272 Lazzaroni, L P234 Lebrecht, D P145, P147, P148 Ledergerber, B O212, O331 Lee, A P203 Lee, V P79 Leen, C P315 Lefebvre, E P157 Lefevre, V P222 Legrand, J P55 Lekander, I P315* Leleu, G O415 Lennemann, T P122 Leoncini, L P69 Letang, E CS1.3, P288* Levy, Y SS1.3Leyes, M P221 Li, J P101 Libertone, R P292 Lim, P P72 Limb, S P203 Lin, S P240 Lin, Y P101 Lins-Filho, A P209 Lisv ka, M P212 Liuzzi, G P292* Llibre, J P42*, P50, P58, P191 Lo Caputo, S P35*, P206 Lo Cicero, M P39 Lobo, J P290* Loeschel, E P83 Logue, K P81 Lonardo, A P139, P140 Longo, N P81 Lopardo, G P317 López, R P65 López-Aldeguer, J P134, P221 Lopez-Bernaldo de Quiros, J

P64 López-Blánquez, R P142López Gomez, M P44 Lorenzini, P P3, P169, P179 Loria, P P139, P140 Losina, E O113 Losso, M O414Loutfy, M P318 Loy, A CS1.1Loyo, K P124 Lozano, F P134 Luechters, G P266 Luminos, M P255 Lundgren, J O212, O312*,

O313, O314, O331, O332,O412, P183

Lutwana, F O125 Lutz, T P12, P13, P25, P59,

P122

Lyall, H O122, O223*, O222,O22CH

Lynen, L P283 Lyons, F P293

Maa, J P8, P61, P63 MacConnachie, A P103, P219,

P225, P253, P291 Machala, L O331, P295 Macias, J P141* Mackie, K P204 Mackintosh, C P253MacPherson, P CoS.3MacRae, K P297 Mactier, H P219, P225 Madeddu, G P19, P74 Madejon, A P284 Madruga, J P4* Maes, P P223 Magafas, N P124 Magenta, A P153 Maggiolo, F O213*, P3, P167* Magiorkinis, E P47, P186 Magiorkinis, G P47, P186 Magnier, J P279 Mahungu, T P238 Mahungu, TW P6*, P250 Maida, I P138*, P286 Mair, R P229 Majluf Cruz, A P104, P108 Makne, A P193 Malashenkov, E O412 Maldonado, M P227 Malincarne, L P10*Mallal, S PCH Mallolas, J P53 Mallon, P O322*, SS6.4Mallon, PW P70 Maltez, F P51Manata, M P51 Mancini, M P136, P180 Manconi, P P133 Mandalia, S P129, P151 Manfredi, R P165* Mangafas, N P105 Manigart, Y P289 Manolescu, L P182*Manonelles, G P227 Mansinho, K P51Manzini, L P273 Manzoli, L P19 Marasca, G P168 Marcas, C P226 Marcelin, A P178 Marchetti, G P1, P88*, P97 Marconi, P P74, P166, P179Marcotullio, S PCHMarczyñska, M O222, P216,

P217*



82



Mardarescu, M P255 Marinescu, P P182 Mariño, A P92 Marks, S P36, P37 Marques, R P51, P296 Márquez, M P141 Marsh, T P110, P170 Martin, S P316 Martin-Carbonero, L P128,

P137, P138, P265, P268 Martinelli, C O213, P74 Martinelli, M P69 Martínez, E SS3.2, P33, P54Martinez, V P269* Martínez-Madrid, O P164,

P254 Martinez-Picado, J P50 Martino, A P213Martino, AM P214 Martins, M O414 Mary-Krause, M P299* Marzocchetti, A P99 Maserati, R P56*, P206* Masini, G P84 Mastronardi, M P69 Mateo, G P67 Matias, R P209 Matos, N P188 Matti, A P52, P267, P282 Mauss, S P12, P41, P135*,

P160*, P195 Mavilla, S P17 Mayer, H O425, P154 Mayer, K P111 Mayr, C P13, P25, P195 Mazeron, M P222, P279 Mazeu, I P156, P177 Mazza, F P31 Mazzocato, V P168 Mazzotta, E P19, P152 Mazzotta, F P35 McCarthy, K P259 McColl, D P61 McConkey, S P109 McDonough, M P190, P192 McGee, K P113 McGrath, D P8, P136, P180,

P185McKenna, P P205, P208 McNally, C P263, P276, P293 Meadway, J P28 Medrano, J P128, P265, P268*,

P284 Meleddu, R P133 Melero, J P251Melza d'Eril, G P235 Mendez, J P51Méndez, I P308* Menendez, C P288

Menichetti, S P292 Menson, E O122 Menzaghi, B P74* Meraviglia, P P31 Merli, S P31 Merlini, E P88, P97 Meroni, L P1 Merritet, J P287 Metallidis, S P124* Miarka, M P258* Micheli, V P31 Michielsen, P P283 Mihailescu, R P255* Miiro, G P11* Milazzo, L P274* Miller, E P57 Miller, M P207 Miller, R O412 Miller, V PCHMills, E P28 Minaeva, S P285* Minguez, C P92 Miralles, C P191 Miralles, P P221 Miranda, A P51* Miranda, C P142 Miro, J O412, P288 Miró, Ò P142, P143, P144,

P146 Mocroft, A O212*, O313,

O331, O332, O412 Modena, M P94 Moeremans, K P313Moerman, F P283 Mofenson, L O222 Moisi, D O114 Mokhtari, Z P269 Mokoka, M P263 Molangeli, S P85 Molina, E P144 Molina, J P2, P24, P269 Moll, A P41 Moltó, J P58, P67, P171, P176 Monia, M P282 Monleón, D P120 Monpoux, F O222 Montaner, J O135*, P271 Monteiro, E P96 Montero, M P130 Montessori, V P271 Moody, D P240 Mora, M P64* Mora, N P213 Morales, J P120 Morales-Ramirez, J P61Morán, A P161 Morello, J P20, P66*Morén, C P142, P143*, P144*,

P146

Moreno, S O415*, SS1CHMoreno, V P128, P286 Mørn, B P90 Moroni, M P1, P39 Morreel, S P228 Morris, J P247 Moshkovich, G P285 Mosthaf, F P13, P25 Mosti, S P166 Mota, M P51 Mounzer, K P63 Mourtzoukos, S P85 Moye, J O222 Moyle, G SS1.2, P98, P129,

P151, P241 Mueller, A P18 Mueller, K P148 Mueller, M P25 Mughini, M P17 Mukhopadhaya, P P193 Mulcahy, F PCH, P76, P91,

P236, P276 Mulder, J P242 Muldoon, E P263* Müller, H P201 Müller, K P145 Munderi, P O125, P11 Muñoz, J P33 Muñoz, L P141 Muñoz-Moreno, J P114*, P171,

P176Muñoz-Sanchez, P P134 Muñoz-Sanz, A P134 Munteanu, D P255 Mura, M P19 Murano, F P227 Murray, J P70 Murri, R P168*, P177 Murungi, A P204, P230*Muscatello, A P168 Mussini, C O33CH, P3, P167,

P273 Mustafa Kambraki, M P214* Muyldermans, G P187, P205 Myer, L P159

Nadal, D O222Nadler, J PCH Nahon, N P209 Nakubulwa, S P11 Nalumenya, R O125 Nandwani, R P103, P219,

P225, P253 Naniche, D P288 Narciso, P P179 Nardini, G P56, P115, P156,

P300 Nasta, P P52, P267*, P282* Naubutu, J P175



83


Navarra, P P243 Navarro, C P64 Naylor, C P110, P170 Necsoi, C P48 Negredo, E P50, P54, P65,

P67, P114, P142, P150 Negroni, R P252 Nelson, M O425, SS1CH,

SS5.1, P14, P16, P49, P98,P116, P127*, P230, P248, P315 Neumann, J P145 Ng, J P245*, P247* Ngo-Giang-Huong, N O222 Nguyen, B P207 Nhassone, D P288 Nhat Vinh, D P77 Nicolàs, M P142, P143, P144,

P146 Niculescu, I P257 Nielsen, H P90 Nieto Cisneros, L P104, P108 Nieves, D P314* Nikolaidis, P P124 Noah, C P62, P201 Noble, H P203 Noertersheuser, P P95, P101 Noguera, A P143, P144 Norton, M P80, P308 Nozza, S P45*, P202* Nuzzo, A P94

O’Connor, E P199 O’Shea, D P276 Oldakowska, A P216, P217 Obbo, J P28 Obel, N O412 Obermeier, M P200 Obermeier, MJ P201* Ocampo, A P42, P221Ocana, I P40 Oelker-Grueneberg, U P163 Olaogun, O P172 Oldakowska, A P217 Oliver, A P203 Olivetti, M P97 Olupot-Olupot, P P28* Omran Al Fituri, O P214Oñate, F P102 Oprea, C P224*Orani, A P56 Orchi, N P169 Orihuela, F P112, P141 Orkin, C P203 Orlando, G P34, P94, P115,

P125, P139, P140, P156*,P177, P300

Orofino, G P74, P167 Orrell, C O113*, O124* Ortega, E P264

Ortí, A P92 Ortu, F P133* Ortu, M P119 Ortu, MO P194* Osiyemi, O O413 Otelea, D P255 Oteo, J P44 Owen, A O121, P233, P237,

P238*

Pacei, M P206 Padiwongpaisarn, W P232 Palacios, R P102*, P112* Palella, F P300 Palermo, F P17 Palma, P P213 Palvarini, L P74 Panagiotidis, J P294 Panagopoulos, P P294 Panagopoulos, PP P124 Pankam, T P259 Panteleev, A O412 Panzner, P P212 Papadopoulos, A P294 Paparizos, V P47, P186 Papili, R P10, P84 Paraschiv, S P255 Paraskevis, D P47*, P186* Parkin, N P197 Parodi, A P215Parruti, G P19*, P152* Pascual-Pareja, J P221 Pasley, M P9 Pasquau, J P65, P78, P141 Pateri, F P235 Patsch, W P200 Pattery, T P187*, P205, P208* Patton, V P219*, P225* Pearce, H P83, P155 Pedicelli, A P99 Pedrol, E P78*, P134, P146 Peeters, M P23, P27, P181*,

P189 Pelgrom, J P223 Pellegrin, I P29 Pellicanò, G P74 Peltzer, K P73 Peña, J P221* Penco, G P74Pereira, S P96* Perez, N P33, P58 Pérez-Álvarez, N P50, P67,

P114, P142, P171, P176, P191 Pérez-Escolano, I P314 Pérez-Pagán, C P164, P254 Perniciaro, A P68 Perno, C SS3.1, P3, P35, P179 Petoumenos, K O314*, P70 Petropoulos, C P197

Pett, S P297* Peytavin, G P29, P38 Phanuphak, N P232, P259 Phanuphak, P P72*, P232,

P244, P259 Phillips, A O212, O333, PCHPhositlimakul, S P259 Pialoux, G O415, P157 Piano, P P133 Picchio, G O424, P181, P189 Pich, J P53 Pieri, A P152 Pierone, G O214 Pierotti, P P35 Pierre, N P29Pierro, P P166, P169 Pietrogrande, L P153 Piliero, P P121, P190*, P192,

P240 Pillay, D O111*, O112 Pineda, J P141, P264 Pinta, A P29 Pippi, R P118 Pitt, J P159* Podlasin, R P258 Podlekareva, D O412*, P6,

P250 Podsadecki, T P170*, P247 Podzamczer, D P53, P92* Poizot, I P26 Pokrovsky, V O415 Pol, S O231* Polilli, E P19, P152 Pollack, S P188 Polsonetti, B O413 Pontrelli, G P213* Popielska, J P217 Portilla, J P141 Portu, J P33 Post, F O412, P260, P262 Poulakou, G P294 Powderly, W O323, O32CH,

P109 Pozniak, A ES2CH, P21, P24*,

P241 Pradier, C O331 Prieto, M P227 Prins, J P155* Prisca, A P296 Prosperi, M P243 Protopas, K P294* Proulx, L P298* Przybylska-Stengiel, K P184 Puerta, S P112 Pugliese, P P26 Puig, J P50, P67, P114, P142,

P150 Puig, T P65 Pujari, S P72, P193*



84



Pulido, F P54, P308 Puoti, M O233*

Quinzan, P O213 Quirino, T P19, P74

Rabelato, J P209 Rachlis, A P22 Radoi, R P224 Radulescu, M P255 Raffa, J P277 Raffi, F ES1.1, ES1.2Ragazzoni, E P243 Rahim, S P307 Rajagopalan, R P307, P311,

P312, P318* Rajicic, N O425, P154, P198 Rakhmanova, A O332 Ramlagan, S P73 Ramos, J P221 Randell, P P129, P151 Ranneberg, B P12*, P76 Rauch, A P155 Ravasio, V O213 Re, M P123 Redfield, R P121 Reekie, J O331* Reeves, I P203 Reeves, J P197* Reichelt, D P163 Reid, A O125 Reiss, P O212, O313, O314,

O332, SS3CH, CS1CH, P27 Resino, S P268 Reynes, J P29* Ribera, E P36, P37*, P40,

P44*, P53, P54*, P65, P134

Ricci, E P74 Richter, C P55 Riddell, L P15Riddler, S P312 Riekstina, V O412 Riera, M P40 Rietz, A P91 Rimsky, L P187, P189 Riordan, A O122 Ríos, M P138, P141 Ristola, M P155 Ritchie, G P271 Rivas, M P40 Rivas, P P128 Rivero, A P141, P314 Rizzardini, G P3, P31 Rizzi, L P234 Rjepaj, K P87 R-Junquera, M P290 Robertson, C P249* Roca, B P134

Roca, V P53 Rocha, M P120 Rocha, S P296 Rochira, V P140 Rock, C P293* Rockstroh, J CS2.3, SS1.1,

SS5.3, SS5CH, SS6CH, P195,P207*, P266*, P304

Rodan, J P112Rode, R P170 Rodkjaer, L P174* Rodrigues-Matias, R P196* Rodriguez-Arrondo, F P33* Rodriguez-Baños, J P64Rodríguez-Nóvoa, S P20, P66,

P128 Rodríguez-Santiago, B P142 Roger, M O114 Rojas, H P252 Roldan, J P102 Romanenko, O P22 Romanescu, A P257 Romero, M P268 Romero, R P284 Romeu, J P142 Rosa, C P42 Rosella, E P74 Rosignoli, D P118 Rosing, H P242 Rosique-Robles, J P162 Rossi, M P99 Rossi, P P213 Rossi, R P94 Rosso, R P215* Rossotti, R P194 Rousseau, E P208 Routy, J O114 Rovira, N P143 Rozsypal, H P295 Ruane, P O413, P68* Rubio, A P66 Rubio, R P54, P83* Rugina, C P226 Rugina, S P226 Ruiz, L P142 Ruiz de Gopegui, E P40 Rusconi, S P39, P194 Russo, R P17 Ruta, S P182, P275 Ruxrungtham, K P157, P244 Ryan, B P37 Ryan, P P137 Ryan, R O413, P36, P68

Sabin, C O314, O422, SS6.1Sabo, J P240 Sa-Filho, D P196, P209 Saghayam, S P111* Saguenwong, N P237

Sahm, L P132 Saidi, Y O222 Sakka, V P294 Salami, O P149* Salmon, D P46, P287 Salpietro, S P45 Salvatori, M P292 Samarawickrama, A P260,

P262 Sambatakou, H P47, P124,

P186 Sampalis, J P81 Sanchez, T P134 Sanchez Vera, M P227 Sandova, O P285 Sandström, E O41CHSang, E O121 Sanne, I O124, P198 Santoro, M P35 Santos, J P102, P112 Santos, JR P58*, P191* Santos, N P209 Santos, S P290 Sanz, J P54, P92, P221, P251Sanz-Moreno, J O415 Sarmento, A P296 Sarmento-Castro, R P51 Sawyer, W P5 Schapiro, J O11CH, P191 Schechter, M PCHScheen, R P289 Schepens, T P228 Scherer, J P190, P192 Scheuerle, A O221 Schewe, K P13 Schiaroli, E P118 Schmidt, E P90 Schmidt, W P7, P75 Schmutz, G P135, P160 Schneider, S P22 Schnepf, N P279* Schrager, H O214 Schwarze-Zander, C P266,

P304 Sciandra, M P233 Sconiamilio, C P34 Scorpan, C P261Scott, C P49*Scott, JD P303*Scourfield, A P14 Seaton, A P103, P219, P225,

P253, P291 Sedláèek, D P212* Seekins, D P61, P185 Sellier, P P279 Seminari, E P30* Serra, P P133 Sette, P P166, P167, P169 Sgrelli, A P10



85


Shahar, E P188 Shahmanesh, M P113 Shallcross, V P238 Shantz, K P229 Sharra, E P87 Sheehan, G P109 Shehu, E P87 Sherlock, C P271 Shewade, A P318 Shingadia, D O122 Shivaji, G P111 Shojaee-Moradie, F P113 Showler, G P277 Siccardi, M P233* Sichtig, N P201 Sighinolfi, L P56 Silberman, B P46 Simon, A P299 Simoneau, G P279 Simpson, K P307*, P311*,

P312* Skiest, D O214 Skrahin, A O412 Smets, E P313*, P316* Smith, B P230 Smith, C O333*, P6, P249,

P250 Soddu, V P19 Sodemann, M P174 Soentjens, P P270 Sogni, P P287 Solera, C P128 Solomon, S P111 Sonecha, S P204*, P230 Sönnerborg, A O11CHSoria, A P45, P202 Soriano, V O232*, P20, P66,P128, P137, P138, P265, P268,

P284, P286 Sorlí, M P130*, P302 Sotgiu, G P56, P138 Sozio, F P19, P152 Spagnuolo, V P202 Spathis, A P294 Spiers, J P91*, P236 Spinosa-Guzman, S P21, P22,

P24, P157 Spire, B CoS.4Spiridon, G P287 Sprenger, H P55* Squillace, N P34, P94, P115*,

P125, P139, P140, P156, P177,P300

Srasuebkul, P P72* Ssali, F O125 Stamatakis, G P105 Stanczak, G P184* Stanczak, J P184 Stankova, M P295

Staszewski, S O41CH, P32, P76, P122

Stellbrink, H ES2.3, P7, P75 Stentarelli, C P34, P94, P115,

P125, P139, P140, P300 Stephan, C P13, P25*, P32*,

P122* Sterrantino, G P3 Stevens, M P239 Stoehr, A P13 Storfer, S O23CHStorms, M P277 Stradling, C P249 Streinu-Cercel, A P255 Stuermer, M P32, P201 Suarez, I P290 Suarez-Lozano, I P134 Suleiman, J P4 Sultana, C P182 Sundaram, M P111 Sungkanuparph, S P72 Suter, F O213 Suwanmala, P P259 Svard, J P236* Svedhem, V P256* Svicher, V P35 Swai, E P175 Sypsa, V P186 Szczepañska-Putz, M P216,

P217

Tagliabue, L P153 Talbird, S P306, P309 Talwani, R P121 Tamburrini, E P168 Tambussi, G P45, P202 Tambuyzer, L P181, P189 Tampellini, L P123 Tappe, A P13, P25, P43 Tardei, G P224, P275 Tasaneeyapan, T P259 Taylor, C O222 Taylor, J P129, P151 Taylor, K P16 Taylor, N P200* Taylor, S P249 Tchidjou, H P213Teeratakulpisarn, N P259* Teicher, E P299 Teira, R P134* Temereanca, A P182 ten Berg, M P60 ten Kate, R P55 ten Napel, C P55 Teofilo, E P51, P76Teppler, H P207ter Heine, R P242*Teresa, B P97 Terron, A P134

Terzi, R P206 Tetradov, S P224 Thal, G P136 Theofilopoulou, A P85 Thi Dieu TA, N P269 Thibert, R P298 Thielen, A P201 Thiry, A P8, P136, P185 Thoden, J P145*, P210 Thompson, M P27 Thornhill, J P276 Thu Thuy, H P77 Thusgaard, M P90* Tikhonova, E P285 Tilekar, S P303 Tilson, H O221 Tincati, C P1*, P88, P97* Tinelli, C P30 Tissot, F P231* Tobara, J P209 Todd, J P11 Toibaro, J O412 Tomaka, F O424, P22 Tomasini, A P177* Tomaszewski, K P154 Tomé, M O222 Tomlinson, J P113 Tookey, P O122 Toraldo, G P118 Torres, R P173 Torres Perea, R P93, P100 Torrisi, C P215 Tossonian, H P277 Toy, J P271 Tozzi, V P179, P292 Treacy, V P132 Trein, A P7, P75 Tressler, R P154, P198 Trevino Perez, S P104, P108 Trinh, L P197 Tripathi, A P158* Trocha, H O332 Trotta, M P166*, P167, P169*,

P179 Trout, H P222 Trujillo-Santos, J P164, P254 Truong Giang, L P77 Trylesinski, A P279 Tsang, A P81Tsiodras, S P294 Tsogas, N P105 Tsoupras, A P105* Tudor-Williams, G O122 Tuma, P P137, P265*, P268,

P284*Tumukunde, D O125 Tural, C P264 Turner, D P188* Turri, O P235



86


Tuyet Nhung, V P77*

Umpleby, A P113 Ungureanu, E P224 Ungurianu, R P255 Uniyal, A P303 Urbankova, O P295 Urbina, O P302 Usadel, S P71 Ushiro-Lumb, I P203 Uy, J P8*, P185*

Vachta, J P43 Vagu, C P182 Vaillancourt, J P81 Valantin, M P26, P269 Valencia, E P128 Vallecillo, G P130 Van Baelen, B O424 Van Cauwenberge, A P205 Van De Casteele, T P21, P24 van Delft, Y P36 Van Den Boer, M P270 Van Der Borght, K P187 van Der Lugt, J P244 Van Der Ryst, E P154 van der Werf, T P55 van Gorp, E P242 van Heeswijk, R P239 Van Houtte, M P187, P205 Van Laethem, Y CS1.4van Lunzen, J O331, O423, P12,

P41, P62 van Solinge, W P60 Van Solingen-Ristea, R P27 van Vugt, M CS1.2Van Walle, I P195 Vanaken, H P36, P37 Vandeloise, E O415Vandevoorde, A P22 Vangeneugden, T O424, P22,

P157 Vannappagari, V O221 Vanveggel, S P2 Varma, J P259 Vecchiet, J P19 Vekemans, M P270, P283 Velasco, M P92 Velat, M P130, P302 Velhal, S P211 Vella, S O21CHVenhoff, A P210 Venhoff, N P145, P147*,

P148*, P210* Vera, J P51, P76

Vera-Méndez, F P164*, P254* Vergara, A P134 Verlinden, Y P187 Vescini, F P123 Vibhagool, A P2 Vichi, F P35, P74 Viciana, P P134, P141 Víctor, V P120 Vidal, F P134 Vidal, I P146 Viergever, R P60* Viganò, O P194, P274 Vige, R P90 Vignolo, M P215 Vilaplana-García, R P164, P254 Villalonga, C P92 Villani, P P234 Villar, J P130, P302 Villar del Saz, S P40 Vinci, C P202 Vingerhoets, J P23, P181,

P189* Vinh Thuy, L P77 Visco, F P45, P202 Visco-Comandini, U P169 Viscoli, C P215 Vispo, E P128, P137, P138,

P265, P268, P284, P286* Vitiello, P P39* Vitiello, PV P194 Vlieghe, E P270, P283 Vogel, M P195, P266 Voigt, E P266, P304 Volkov, Y P91 Volny-Anne, A PCH, CoSCHvon Hentig, N P32, P122 Voorspoels, E P27 Vriesendorp, R P55

Wainberg, M O114* Walensky, R O113 Walker, AS O122*, O125 Walker, U P145, P147, P148,

P210 Walli, R P86 Walter, H P201 Wan, H P207 Wangpatharawanit, P P232* Wanke, C P111 Ward, D P57* Wasmuth, J P266, P304 Watera, C P11 Waters, L O422*, SS4.1,

P129*, P151* Watts, D O221

Weber, R O314, O32CH, P27 Weller, IVD O22CH, O42CHWellmann, E P13, P25 Wendig, A P122 Weston, R P204 Whitcomb, J P197 White, B P291* Whiteside, A KL3* Wiercinska-Drapalo, A O212,

P184 Wiesmann, F P43 Wilkins, E ES1CH, ES1.4Williams, I O324*, CS2.2,

CS2CHWilliams, P P2 Winston, A P260, P301 Winter, A P103, P219, P225,

P253 Wintergerst, U O222 Wirden, M P29, P38 Witek, J O413, P68 Wolf, E P7*, P13, P25, P195*,

P201 Wongsuthipol, C P259 Wood, C O422 Wood, R O113, O123, O134*,

P159, P198 Woodward, W P9 Workman, C P22 Worm, S O314Wouters, K P223 Wrin, T P197 Wruck, J P240

Xerinda, S P296 Xilomenos, G P124 Xynos, K P124

Yang, R P8, P136, P180 Yazdanpanah, Y P26, P195 Yerrakalva, D P301 Youle, M O333, P6, P250 Young, B P61*

Zaccarelli, M P166, P169, P179*

Zaunders, J P297 Zetehaku, A P209* Zhou, Y P4 Zicolella, R P152 Zimovetz, E P306 Zirilli, L P140 Zona, S P34, P94, P115, P125,

P139, P140, P177, P300 Zoufaly, A O423*


AUTHOR INDEX (continued)Name Activity Name Activity Name Activity

Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly...

Documents

Transcript of Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly...